How to buy Biogen (BIIB) shares in Australia

Learn how to easily invest in Biogen shares.

Biogen Inc
NASDAQ: BIIB - USD
DRUG MANUFACTURERS-GENERAL
$281.19
- $4.07 ( - 1.43%)

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Biogen Inc (BIIB) is a leading drug manufacturers-general business with stocks listed in the US. It opened the day at US$300.85 after a previous close of US$299.69. During the day the price has varied from a low of USD296.56 to a high of USD300.85. The latest price was USD300.19 (25 minute delay). Biogen is listed on the NASDAQ. All prices are listed in US Dollars.

How to buy shares in Biogen

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Biogen. Find the share by name or ticker symbol: BIIB. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Biogen reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$299.69, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Biogen, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Biogen. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Biogen stock price (NASDAQ:BIIB)

Use our graph to track the performance of BIIB stocks over time.

Biogen shares at a glance

Information last updated 2021-09-17.
OpenUS$300.85
HighUS$300.85
LowUS$296.56
CloseUS$300.19
Previous closeUS$299.69
Change US$0.5
Change % 0.1668%
Volume 1,680,045
Information last updated 2021-10-15.
52-week rangeUS$223.25 - US$427.5
50-day moving average US$300.7924
200-day moving average US$312.6355
Target priceUS$397.48
PE ratio 22.488
Dividend yield N/A (0%)
Earnings per share (TTM) US$12.504

Where to buy Biogen stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
US$0
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
US$0
0.70%
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
US$0
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares
Australia’s lowest-cost broker for ASX shares and ETFs.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
SelfWealth (Basic account)
US$9.5
0.60%
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Saxo Capital Markets (Classic account)
US$4
1%
ASX shares, Global shares, Forex, CFDs, Margin trading, Options trading, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
CMC Markets Invest
US$0
0.60%
ASX shares, Global shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 9,000 products, including shares, ETFs and managed funds, plus access up to 15 major global and Australian stock exchanges.
loading

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Biogen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Biogen share growth calculator

US$

Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Considering buying Biogen shares?

Before you consider Biogen, you'll want to hear this.
Ticker Nerd uses advanced software to track hundreds of signals and data points to find stocks before they blow up. You can get the next two hot stocks they find sent to your inbox for free.

Show me how

Biogen price performance over time

Historical closes compared with the last close of $300.19

1 month (2021-09-17) 300.19
3 months (2021-07-17) -13.92%
6 months (2021-04-16) 11.05%
1 year (2020-10-16) 7.21%
2 years (2019-10-17) 33.06%
3 years (2018-10-17) -11.25%
5 years (2016-10-17) 11.74%

Stocks similar to Biogen

Is Biogen under- or over-valued?

Valuing Biogen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biogen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Biogen's P/E ratio

Biogen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 22x. In other words, Biogen shares trade at around 22x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Biogen's PEG ratio

Biogen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.2424. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Biogen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Biogen's EBITDA

Biogen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$3.3 billion (£2.4 billion).

The EBITDA is a measure of a Biogen's overall financial performance and is widely used to measure a its profitability.

Biogen financials

Revenue TTM US$11.7 billion
Operating margin TTM 24.03%
Gross profit TTM US$11.6 billion
Return on assets TTM 7.03%
Return on equity TTM 22.14%
Profit margin 16.4%
Book value 72.112
Market capitalisation US$41.9 billion

TTM: trailing 12 months

Shorting Biogen shares

There are currently 2.5 million Biogen shares held short by investors – that's known as Biogen's "short interest". This figure is 1.8% up from 2.4 million last month.

There are a few different ways that this level of interest in shorting Biogen shares can be evaluated.

Biogen's "short interest ratio" (SIR)

Biogen's "short interest ratio" (SIR) is the quantity of Biogen shares currently shorted divided by the average quantity of Biogen shares traded daily (recently around 1.1 million). Biogen's SIR currently stands at 2.35. In other words for every 100,000 Biogen shares traded daily on the market, roughly 2350 shares are currently held short.

However Biogen's short interest can also be evaluated against the total number of Biogen shares, or, against the total number of tradable Biogen shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biogen's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Biogen shares in existence, roughly 20 shares are currently held short) or 0.0167% of the tradable shares (for every 100,000 tradable Biogen shares, roughly 17 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biogen.

Find out more about how you can short Biogen stock.

Biogen's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Biogen.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Biogen's total ESG risk score

Total ESG risk: 22.95

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Biogen's overall score of 22.95 (as at 12/31/2018) is pretty good – landing it in it in the 34th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Biogen is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Biogen's environmental score

Environmental score: 1.02/100

Biogen's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Biogen's social score

Social score: 13.48/100

Biogen's social score of 13.48 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Biogen is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Biogen's governance score

Governance score: 7.45/100

Biogen's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Biogen is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Biogen's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Biogen scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Biogen has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Biogen Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.95
Total ESG percentile 33.82
Environmental score 1.02
Environmental score percentile 2
Social score 13.48
Social score percentile 2
Governance score 7.45
Governance score percentile 2
Level of controversy 2

Biogen share dividends

We're not expecting Biogen to pay a dividend over the next 12 months.

Have Biogen's shares ever split?

Biogen's shares were split on a 3:1 basis on 17 January 2001. So if you had owned 1 share the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Biogen shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for Biogen shares which in turn could have impacted Biogen's share price.

Biogen share price volatility

Over the last 12 months, Biogen's shares have ranged in value from as little as US$223.25 up to US$427.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biogen's is 0.4704. This would suggest that Biogen's shares are less volatile than average (for this exchange).

Biogen overview

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site